GlassScriptPhysician profile
China H Phillips
NPI 1053505768
$5,335.65
in general payments reported to CMS, 2019-2025
29 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $688 · 2022: $1,235 · 2023: $818 · 2024: $1,192 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $546.56 | 2023-2025 | Tagrisso, Enhertu |
| Neurocrine Biosciences, INC. | $449.85 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $361.69 | 2022-2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $321.66 | 2024-2025 | |
| Abbott Laboratories | $307.07 | 2023 | Freestyle Libre 3 |
| Adc Therapeutics America, INC. | $247.32 | 2024-2025 | |
| Novo Nordisk INC | $237.47 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $237.09 | 2022-2025 | Austedo Xr |
| Lilly USA, LLC | $209.43 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $182.97 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.49 | 2021-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $153.23 | 2022-2024 | Libtayo |
| Incyte Corporation | $146.37 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $142.98 | 2025 | Rybrevant |
| Eisai INC. | $125.00 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $124.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2022 | |
| Axsome Therapeutics, INC. | $124.37 | 2025 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $123.51 | 2024 | Inpefa |
| Biohaven Pharmaceuticals, INC. | $121.60 | 2021 | |
| Sobi, INC | $120.43 | 2024 | |
| Inspire Medical Systems, INC. | $118.76 | 2023 | Inspire |
| Dexcom, INC. | $115.19 | 2024 | Dexcom G7 Gss (161) |
| Neurelis, INC. | $111.25 | 2023 | Valtoco |
| Genzyme Corporation | $99.48 | 2022 | |
| Pharmacosmos Therapeutics INC. | $96.60 | 2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $88.27 | 2024 | |
| Daiichi Sankyo INC. | $84.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw China Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.